GALT - Galectin Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development6,47111,72115,32513,114
Selling General and Administrative7,1314,5266,1566,965
Non Recurring----
Others----
Total Operating Expenses13,60216,24721,48120,079
Operating Income or Loss-13,602-16,247-21,481-20,079
Income from Continuing Operations
Total Other Income/Expenses Net-298124552
Earnings Before Interest and Taxes-13,602-16,247-21,481-20,079
Interest Expense-336-12-12-12
Income Before Tax-13,900-16,235-21,436-20,027
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-13,900-16,235-21,436-20,027
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-13,900-16,235-21,436-20,027
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-15,047-17,467-22,350-21,124